Brian S Kim1, Michael D Howell2, Kang Sun2, Kim Papp3, Adnan Nasir4, Michael E Kuligowski2. 1. Washington University School of Medicine, St Louis, Mo. Electronic address: briankim@wustl.edu. 2. Incyte Corporation, Wilmington, Del. 3. K. Papp Clinical Research and Probity Medical Research, Waterloo, Ontario, Canada. 4. Wake Research Associates LLC, Raleigh, NC.
Abstract
BACKGROUND: Atopic dermatitis (AD) is a highly pruritic chronic inflammatory skin disorder. Ruxolitinib, a selective inhibitor of Janus kinase 1 and Janus kinase 2, potently suppresses cytokine signaling involved in AD pathogenesis. OBJECTIVE: We sought to evaluate the efficacy and safety of ruxolitinib (RUX) cream in adults with AD. METHODS: In this phase 2 study (NCT03011892), 307 adult patients with AD, an Investigator's Global Assessment score of 2 or 3 (mild or moderate), and 3% to 20% affected body surface area were equally randomized for 8 weeks of double-blind treatment to RUX (1.5% twice daily [BID], 1.5% once daily [QD], 0.5% QD, 0.15% QD), vehicle, or triamcinolone cream (0.1% BID for 4 weeks, then vehicle for 4 weeks). Subsequently, patients could apply 1.5% RUX BID for 4 additional weeks of open-label treatment. The primary end point was the comparison between 1.5% RUX cream BID and vehicle in mean percentage change from baseline in Eczema Area and Severity Index at week 4. RESULTS: All RUX regimens demonstrated therapeutic benefit at week 4; 1.5% BID provided the greatest improvement in Eczema Area and Severity Index (71.6% vs 15.5%; P < .0001) and Investigator's Global Assessment responses (38.0% vs 7.7%; P < .001) versus vehicle. Rapid reductions in the itch numerical rating scale score occurred within 36 hours (1.5% BID vs vehicle, ‒1.8 vs ‒0.2; P < .0001) and were sustained through 12 weeks. Patients who transitioned to 1.5% RUX BID improved in all measures. RUX was not associated with clinically significant application-site reactions. CONCLUSIONS:RUX cream provided rapid and sustained improvements in AD symptoms and was well tolerated.
RCT Entities:
BACKGROUND:Atopic dermatitis (AD) is a highly pruritic chronic inflammatory skin disorder. Ruxolitinib, a selective inhibitor of Janus kinase 1 and Janus kinase 2, potently suppresses cytokine signaling involved in AD pathogenesis. OBJECTIVE: We sought to evaluate the efficacy and safety of ruxolitinib (RUX) cream in adults with AD. METHODS: In this phase 2 study (NCT03011892), 307 adult patients with AD, an Investigator's Global Assessment score of 2 or 3 (mild or moderate), and 3% to 20% affected body surface area were equally randomized for 8 weeks of double-blind treatment to RUX (1.5% twice daily [BID], 1.5% once daily [QD], 0.5% QD, 0.15% QD), vehicle, or triamcinolone cream (0.1% BID for 4 weeks, then vehicle for 4 weeks). Subsequently, patients could apply 1.5% RUX BID for 4 additional weeks of open-label treatment. The primary end point was the comparison between 1.5% RUX cream BID and vehicle in mean percentage change from baseline in Eczema Area and Severity Index at week 4. RESULTS: All RUX regimens demonstrated therapeutic benefit at week 4; 1.5% BID provided the greatest improvement in Eczema Area and Severity Index (71.6% vs 15.5%; P < .0001) and Investigator's Global Assessment responses (38.0% vs 7.7%; P < .001) versus vehicle. Rapid reductions in the itch numerical rating scale score occurred within 36 hours (1.5% BID vs vehicle, ‒1.8 vs ‒0.2; P < .0001) and were sustained through 12 weeks. Patients who transitioned to 1.5% RUX BID improved in all measures. RUX was not associated with clinically significant application-site reactions. CONCLUSIONS:RUX cream provided rapid and sustained improvements in AD symptoms and was well tolerated.
Authors: El-Bdaoui Haddad; Sonya L Cyr; Kazuhiko Arima; Robert A McDonald; Noah A Levit; Frank O Nestle Journal: Dermatol Ther (Heidelb) Date: 2022-05-21
Authors: Fang Wang; Anna M Trier; Fengxian Li; Seonyoung Kim; Zhen Chen; Jiani N Chai; Madison R Mack; Stephanie A Morrison; Jennifer D Hamilton; Jinok Baek; Ting-Lin B Yang; Aaron M Ver Heul; Amy Z Xu; Zili Xie; Xintong Dong; Masato Kubo; Hongzhen Hu; Chyi-Song Hsieh; Xinzhong Dong; Qin Liu; David J Margolis; Marius Ardeleanu; Mark J Miller; Brian S Kim Journal: Cell Date: 2021-01-14 Impact factor: 66.850
Authors: Yi Li; Lina Wei; Marie-Charlotte Meinsohn; Rana Suliman; Maeva Chauvin; Jim Berstler; Kate Hartland; Mark M Jensen; Natalie A Sicher; Nicholas Nagykery; Patricia K Donahoe; David Pepin Journal: Proc Natl Acad Sci U S A Date: 2022-04-05 Impact factor: 12.779